From receptor biology to therapy: importance of different EGFR mutations in the development of targeted cancer therapies.

Krishnaja U, J N, Sarkar M, Menon KN, Kalita B

Open source

DOI
10.1080/1750743x.2026.2728525
Published
2026 Sep 15
Container
Immunotherapy
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1080/1750743x.2026.2728525,
  title = {From receptor biology to therapy: importance of different EGFR mutations in the development of targeted cancer therapies.},
  author = {Krishnaja U and J N and Sarkar M and Menon KN and Kalita B},
  year = {2026},
  journal = {Immunotherapy},
  doi = {10.1080/1750743x.2026.2728525},
  url = {https://doi.org/10.1080/1750743x.2026.2728525}
}

RIS

TY  - JOUR
TI  - From receptor biology to therapy: importance of different EGFR mutations in the development of targeted cancer therapies.
AU  - Krishnaja U
AU  - J N
AU  - Sarkar M
AU  - Menon KN
AU  - Kalita B
PY  - 2026
JO  - Immunotherapy
DO  - 10.1080/1750743x.2026.2728525
UR  - https://doi.org/10.1080/1750743x.2026.2728525
ER  - 

APA

U, K., N, J., M, S., KN, M., & B, K. (2026). From receptor biology to therapy: importance of different EGFR mutations in the development of targeted cancer therapies.. Immunotherapy. https://doi.org/10.1080/1750743x.2026.2728525

Source records